Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

Nasopharyngeal cancer refers to a relatively uncommon malignancy that begins in the nasopharynx—the upper section of the throat located behind the nose and above the back of the mouth. To understand ...

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...

DelveInsight's, “Nasopharyngeal Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the ...

Positive opinion for TEVIMBRA in combination with chemotherapy as a first-line treatment of nasopharyngeal cancer (NPC) based on results of RATIONALE-309 study demonstrating statistically significant ...

Researchers are continuing to study nasopharyngeal carcinoma (NPC) to understand how it develops and what it responds to. Their goal is to provide better outcomes and possible prevention. NPC is a ...

Treatments for metastatic or recurrent nasopharyngeal carcinoma (NPC) may include chemotherapy, radiation, surgery, targeted drug therapy, and immunotherapy. NPC is a cancer that occurs in the head ...

Credit: Coherus BioSciences. Coherus has launched the Loqtorzi Solutions program, which provides support services to prescribers and patients. Loqtorzi (toripalimab-tpzi) is now available for the ...

Statin use during concurrent chemoradiotherapy (CCRT) for advanced nasopharyngeal cancer (NPC) is associated with a 52% reduction in all-cause mortality. Higher cumulative defined daily doses of ...